Despite the literature data showing that choline-PET/CT performance in recurrent prostate cancer may be influenced by the PSA level [9,13], as is the case with PSMA-PET [14], we did not evaluate for such a relationship in our study, further than demonstrating a non-significant difference between accurately and non-accurately assessed patients due to the small sample size. This evidence concerns the gene FOLH1 and prostate cancer.